11/20
07:07 am
nams
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH [Yahoo! Finance]
High
Report
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH [Yahoo! Finance]
11/20
07:00 am
nams
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
High
Report
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
11/19
08:00 am
nams
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors
Medium
Report
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors
11/18
03:26 pm
nams
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 [Yahoo! Finance]
Low
Report
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 [Yahoo! Finance]
11/18
03:20 pm
nams
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
Low
Report
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
11/11
06:14 am
nams
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate [Yahoo! Finance]
Low
Report
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate [Yahoo! Finance]
11/7
08:36 am
nams
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
Medium
Report
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
11/6
08:00 am
nams
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
High
Report
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
11/1
05:26 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/28
04:30 pm
nams
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
Low
Report
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
10/4
04:30 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/23
08:53 am
nams
NewAmsterdam Pharma (NASDAQ: NAMS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $37.00 price target on the stock.
Low
Report
NewAmsterdam Pharma (NASDAQ: NAMS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $37.00 price target on the stock.
9/7
08:42 am
nams
While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership [Yahoo! Finance]
Low
Report
While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership [Yahoo! Finance]
9/6
04:32 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/5
12:10 pm
nams
NewAmsterdam Pharma (NASDAQ: NAMS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $31.00 price target on the stock.
Low
Report
NewAmsterdam Pharma (NASDAQ: NAMS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $31.00 price target on the stock.
8/30
04:52 pm
nams
ESC 2024: Obicetrapib – a promising breakthrough for dyslipidemia treatment [Yahoo! Finance]
Medium
Report
ESC 2024: Obicetrapib – a promising breakthrough for dyslipidemia treatment [Yahoo! Finance]
8/30
08:00 am
nams
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
Medium
Report
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
8/28
01:44 pm
nams
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside [Yahoo! Finance]
Low
Report
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside [Yahoo! Finance]
8/28
08:06 am
nams
NewAmsterdam Pharma (NASDAQ: NAMS) is now covered by analysts at Needham & Company LLC. They set a "buy" rating and a $36.00 price target on the stock.
Medium
Report
NewAmsterdam Pharma (NASDAQ: NAMS) is now covered by analysts at Needham & Company LLC. They set a "buy" rating and a $36.00 price target on the stock.